Skip to main content

Market Overview

AstraZeneca, JNJ To Start Research On Potentially Modified COVID-19 Shots: WSJ

Share:
AstraZeneca, JNJ To Start Research On Potentially Modified COVID-19 Shots: WSJ
  • Johnson & Johnson (NYSE: JNJ) and AstraZeneca plc (NASDAQ: AZN) have joined the University of Oxford and other experts to conduct early-stage research to assess if modifications to their COVID-19 vaccines could reduce or eliminate risks of rare blood clotting events linked to the shots.
  • The studies on clues for clot formation are fueling the hopes of identifying the cause with potential for reengineering the AstraZeneca vaccine by next year, the Wall Street Journal reported citing people familiar with the matter.
  • According to data from the U.K. and Europe, the incidence of blood clotting combined with low platelet count stands at 1 to 2 per 100,000 AstraZeneca shots. a
  • U.S. government data indicate that the rate is 0.3 cases per 100,000 doses for the JNJ vaccine.
  • Both vaccines are based on an adenovirus vector.
  • According to a recent Canadian study, a handful of amino acids could offer new clues on reasons for vaccine-induced clotting.
  • Price Action: AZN stock is down 0.15% at $60.41, while JNJ stock is up 0.08% at $169.35 during the market session on the last check Tuesday.
 

Related Articles (AZN + JNJ)

View Comments and Join the Discussion!

Posted-In: Briefs COVID-19 Vaccine Wall Street JournalBiotech News Health Care General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com